PT  - JOURNAL ARTICLE
AU  - Min Seo Kim
AU  - Soon-Woo Jang
AU  - Yu-Kyung Park
AU  - Bong-Ok Kim
AU  - Tae-Ho Hwang
AU  - Seok Ho Kang
AU  - Won Jun Kim
AU  - Park Sung Kyu
AU  - Hea-Woon Park
AU  - Wonjong Yang
AU  - Joonyoung Jang
AU  - Min Ho An
TI  - Treatment Response to Hydroxychloroquine, Lopinavir–Ritonavir, and Antibiotics for Moderate COVID-19: A First Report on the Pharmacological Outcomes from South Korea
AID  - 10.1101/2020.05.13.20094193
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.13.20094193
4099  - http://medrxiv.org/content/early/2020/06/14/2020.05.13.20094193.short
4100  - http://medrxiv.org/content/early/2020/06/14/2020.05.13.20094193.full
AB  - The authors have withdrawn this manuscript because of the controversy about hydroxychloroquine and potential changes in results after peer-review, the authors intend to share their results in formal publication. Therefore, the authors do not wish this work to be cited as reference for the project. If you have any questions, please contact the corresponding author.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo supported fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committee of Pusan National University Yangsan Hospital, Pusan, Korea approved this study and granted a waiver of informed consent from study participantsAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesA retrospective cohort study of 358 patients with laboratory-confirmed SARS Cov 2 infection hospitalized in Korea Workers Compensation and Welfare Service Daegu Hospital was conducted